Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus

Medicus Pharma (MDCX) outlined its strategy to advance clinical and regulatory milestones, focusing on partnerships and licensing deals. The company's pipeline includes CD228V for melanoma and other cancers, and SkinJect for Gorlin syndrome. Medicus has raised $90M to support development and operations, according to the shareholder update.

Medicus Pharma (MDCX) proposed a redesigned trial for its prostate cancer drug Teverelix, aiming to cut enrollment by 60% and position it for licensing. The company submitted a Phase 2b/3 protocol to the FDA, seeking to reduce development time and costs. The FDA has not yet agreed to the proposed pathway. Medicus plans to use the feedback to attract a pharmaceutical partner.

Medicus Pharma (MDCX) submitted a Phase 2b/3 trial design for Teverelix to the FDA, aiming to reduce the patient count from 1,500 to 600. The trial focuses on prostate cancer patients with cardiovascular risk. The company seeks a strategic partner for the program, with clinical readiness expected by year-end. FDA approval is not guaranteed, and no licensing deal is assured.

Medicus Pharma (MDCX) will focus SkinJect development exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions, per its portfolio strategy. The FDA's concerns and the company's engagement with the agency influenced this decision. The Gorlin program follows a completed Phase 2 study and an authorized Phase 2b study set for July 2026.

Medicus Pharma (MDCX) reported progress in its SkinJect program, confirming a 200-microgram patch dose for further studies. The company is focusing on Gorlin syndrome and seeking a partner for nodular basal cell carcinoma. A potential partnership could bring $25,000+ in reimbursement. Additionally, MDCX is collaborating with Pfizer on a CD228-targeted antibody-drug conjugate for melanoma and solid tumors, receiving $2M in funding.

Medicus Pharma (MDCX) reported positive Phase 2 trial results for SkinJect in treating skin cancer, with all 90 patients completing treatment. The company plans to advance a 200-microgram dose in a registrational trial for Gorlin syndrome and seek a partner for broader use. The FDA cleared the SKNJCT-005 study, with potential peak US revenue estimated at $383 million.